Overview

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.
Phase:
N/A
Details
Lead Sponsor:
University of Washington
Collaborators:
Abbott
American Diabetes Association
Medtronic
Treatments:
Glipizide
Linagliptin